Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457808 · ClinicalTrials.gov registry record · Phase 2
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
A Phase 2 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00457808 is a Phase 2 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 25 participants.
The verdict
NCT00457808, a Phase 2 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.
Interventions
- DRUG Rapamycin, sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-12 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00457808
The ClinicalTrials.gov registry entry for NCT00457808 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rapamycin, sirolimus is the first listed.
NCT00457808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00457808 about?
NCT00457808 is a clinical study titled "Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM". The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.
What is the current status of trial NCT00457808?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2002-12. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00457808?
The interventions under investigation include: Rapamycin, sirolimus (DRUG).
Who is sponsoring clinical trial NCT00457808?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.